As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Study of Transient Myeloproliferative Disorder in Children with Down Syndrome
Transient myeloproliferative disease (TMD) has been estimated to occur in up to 10% of infants with Down syndrome (DS). TMD is a heterogeneous disease, which encompasses a spectrum of clinical presentations. Some infants appear healthy and are diagnosed with TMD due to the incidental finding of circulating leukemia cells on a peripheral blood smear. Other infants with TMD either die inutero or are born critically ill with severe hydrops, organomegaly, and hepatic fibrosis with liver failure. Approximately 30% of TMD survivors develop leukemia later in life.
The biological determinants of these vast differences in clinical presentation and disease free survival are not understood. Thus, the primary goal of this study is to link the clinical characteristics of TMD patients to the biological features of this disease, defining the relationship between molecular properties and outcome in this unique patient population.
In order to participate you must meet the following criteria:
- Are less than 90 days of age at diagnosis of TMD.
Have a diagnosis of TMD defined as the following:
- A diagnosis of Down syndrome or Down syndrome mosaicism. Patients may be enrolled on study prior to cytogenetic or FISH confirmation of the diagnosis if the typical physical characteristics of Down syndrome are present (see Appendix II). However confirmation of diagnosis must occur within 21 days of enrollment.
- Non-erythroid and non-lymphoid blasts (any amount) in the peripheral blood verified with a second sample.
This is a partial list of elgibility requirements.